Overview

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2003-11-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial of vaccine therapy plus sargramostim following chemotherapy in treating patients who have previously untreated aggressive non-Hodgkin's lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Nebraska

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cyclophosphamide
Doxorubicin
Keyhole-limpet hemocyanin
Liposomal doxorubicin
Mitoxantrone
Prednisone
Sargramostim
Vaccines
Vincristine